FibroGen To Report Third Quarter 2016 Financial Results On November 8, 2016

SAN FRANCISCO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that FibroGen will report third quarter 2016 financial results on Tuesday, November 8, 2016, after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. Eastern Time  (1:30 p.m. Pacific Time).

Audio Webcast Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast will be available on the investor section of the company's website for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use the passcode 43661114#.

Dial-In InformationLive (US/Canada): (888) 771-4371Live (International): (847) 585-4405Passcode: 43661114

About FibroGenFibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company utilizes its extensive experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate development programs in multiple therapeutic areas. Its most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases, or HIF-PHs, in Phase 3 clinical development for the treatment of anemia in CKD. A second product candidate, FG-3019, or pamrevlumab, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy. For more information please visit: www.fibrogen.com.

ContactKaren L. BergmanVice President, Investor Relations and Corporate CommunicationsFibroGen, Inc.415-978-1433kbergman@fibrogen.com

Primary Logo

If you liked this article you might like

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Magellan Midstream, Walt Disney, Align Technology: 'Mad Money' Lightning Round

Magellan Midstream, Walt Disney, Align Technology: 'Mad Money' Lightning Round

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Kratos Defense, Fibrogen, Nike: 'Mad Money' Lightning Round

Kratos Defense, Fibrogen, Nike: 'Mad Money' Lightning Round